Accutane (isotretinoin) helps only a minority of people with hidradenitis suppurativa. In a systematic review and meta-analysis, roughly 30% of HS patients treated with isotretinoin showed complete or partial improvement, while about 57% had no response at all. That’s a stark contrast to its near-legendary success rate for severe acne, and the difference comes down to what’s actually driving each disease.
Why Accutane Works for Acne but Often Fails for HS
Accutane’s superpower is shrinking oil glands and slashing sebum production. In acne, that cuts off the fuel supply for clogged pores and bacterial overgrowth, which is why it clears severe acne so reliably. HS shares some surface similarities with acne: both involve blocked hair follicles and painful inflammation. But HS is a fundamentally different disease.
In HS, the core problem starts with abnormal skin cell turnover inside hair follicles. Cells build up, plug the follicle, and the follicle swells until it ruptures. That rupture spills debris into surrounding tissue and triggers an aggressive immune response, leading to the deep abscesses, tunnels, and scarring that define HS. The inflammation in HS is driven primarily by an overactive immune system, not by oil production. And the glands most involved in HS are apocrine sweat glands, not the sebaceous (oil) glands that Accutane targets so effectively.
Accutane does have some anti-inflammatory properties. It can reduce several key inflammatory signals involved in HS, and it can help normalize the way skin cells mature inside follicles, potentially reducing the plugging that starts the whole process. These effects explain why some patients do see improvement. But for most people with HS, the immune-driven inflammation is simply too dominant for Accutane’s mechanisms to make a meaningful dent.
Who Is Most Likely to Respond
Disease severity is the strongest predictor of whether Accutane will help. HS is classified into three Hurley stages: stage I (isolated abscesses without scarring or sinus tracts), stage II (recurring abscesses with some scar tissue and tunnel formation), and stage III (widespread interconnected tracts and scarring across an entire area). In retrospective studies, complete responses to isotretinoin occurred only in patients with stage I or stage II disease. Patients with stage III HS made up half of all non-responders.
This makes intuitive sense. Early-stage HS is closer to a follicular plugging problem, which is where Accutane has the most to offer. By the time HS reaches stage III, the disease is dominated by deep immune activity, extensive scarring, and tunneling that no pill can reverse.
Body composition and HS subtype also matter. One study of 82 patients found that the factor most strongly linked to a poor response was having what researchers call a “conglobata phenotype,” a pattern of HS that features large, deep, interconnected nodules. Having a BMI above 25 also predicted worse outcomes. Among the 26 patients in that study who received isotretinoin after their HS had already begun, only 6 (about 23%) reported that it helped their HS at all. Male patients were also more likely to experience worsening.
Can Accutane Make HS Worse?
This is an underappreciated risk. In some patients, isotretinoin doesn’t just fail to help HS; it can actually aggravate it. In that same study, about 12% of HS patients taking isotretinoin for coexisting acne reported that their acne worsened on the medication. Nine out of ten of those patients were men, and 80% had the conglobata phenotype. Some dermatologists now argue that isotretinoin should be avoided entirely in HS patients with that particular disease pattern, even when the goal is treating acne rather than HS itself.
What Treatment Looks Like
When isotretinoin is tried for HS, it is typically prescribed at doses between 0.7 and 1.2 mg per kilogram of body weight per day, taken for about four months. This is similar to acne dosing. The side effects are the same ones familiar to anyone who has taken Accutane: dry skin, dry lips, joint aches, sensitivity to sun, and mandatory pregnancy prevention due to the risk of severe birth defects. Monthly blood tests to monitor liver function and lipid levels are standard.
There is limited data on exactly how quickly HS patients who do respond will notice improvement. Unlike acne, where most patients see noticeable clearing within two to three months, HS responses are less predictable and the existing studies don’t report clear timelines.
How Accutane Compares to Other Retinoids
Accutane is not the only vitamin A derivative used for HS. Acitretin, a related retinoid, works through slightly different pathways and has shown better results in pooled analyses. While isotretinoin produced improvement in about 30% of patients, acitretin’s response rates have been notably higher in the available literature. Acitretin has stronger effects on skin cell differentiation throughout the body, which may make it better suited to the widespread keratinization problems seen in HS. If your dermatologist is considering a retinoid for your HS, acitretin is generally the preferred option.
Where Accutane Fits in HS Management
Isotretinoin is not a first-line treatment for HS in any major clinical guideline. The go-to medical therapies for HS include antibiotics (both topical and oral) for mild to moderate disease, and biologic medications that target specific immune pathways for moderate to severe cases. These biologics block the inflammatory signals that drive HS flares and have significantly higher response rates than isotretinoin.
Accutane tends to come up in two scenarios. The first is when a patient has both HS and severe acne, and the acne needs treatment. In that case, the prescriber should carefully evaluate the HS subtype before starting, since the conglobata phenotype raises the risk of worsening. The second scenario is mild, early-stage HS where the dominant feature is follicular plugging rather than deep inflammation, and first-line treatments haven’t worked. Even then, expectations should be realistic: the odds favor no response, and the roughly 30% chance of improvement is partial improvement in many of those cases, not a cure.
For most people with HS, Accutane is not the answer. But for a specific subset, those with early-stage disease, a regular (non-conglobata) phenotype, and a normal BMI, it remains a reasonable option to discuss with a dermatologist who has experience managing HS.